StratifAI

About StratifAI

StratifAI is a German digital health company founded in 2023 by Omar El Nahhas (CEO), Firas Khader (CSO), Jakob Nikolas Kather, and Daniel Truhn. The company's origins trace back to foundational research in computational pathology conducted by the founders' university research groups starting in 2018.

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Its discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers.

Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, helping refine adjuvant treatment options. Retrospectively validated on thousands of patients from Phase III trials and in real-world clinical settings, Polaris™ Breast is available for research-use only and is undergoing regulatory approval in the EU and US.

In September 2024, StratifAI secured €1.5 million (approximately $1.66 million) in a pre-seed funding round. The round was co-led by Neulogy Ventures and MultiplexDX, with participation from Debiopharm Innovation Fund, Arve Capital, and angel investor Christoph Haarburger. In September 2025 StratifAI announced closing €12.5M for clinical validation of AI biomarker platform Polaris™. Oversubscribed round was led by Picus Capital, with co-lead Alven, alongside Heliad, Rubin Ritter, Lars Langusch, and Jens Begemann. Existing backers Debiopharm, Arve Capital, Christoph Haarburger also joined, deepening their commitment to StratifAI’s vision.